(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -19.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Metagenomi's revenue in 2025 is $52,295,000.On average, 4 Wall Street analysts forecast MGX's revenue for 2025 to be $1,246,551,874, with the lowest MGX revenue forecast at $627,294,660, and the highest MGX revenue forecast at $1,742,069,795. On average, 3 Wall Street analysts forecast MGX's revenue for 2026 to be $1,430,291,639, with the lowest MGX revenue forecast at $627,294,660, and the highest MGX revenue forecast at $2,542,076,096.
In 2027, MGX is forecast to generate $627,294,660 in revenue, with the lowest revenue forecast at $627,294,660 and the highest revenue forecast at $627,294,660.